Metabolic Research
Retatrutide — 15mg
$130
The 15mg vial format of retatrutide, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist — a mid-to-high concentration option for metabolic research protocols spanning the upper end of the clinical dose-escalation range.
Metabolic ResearchOverview
Retatrutide 15mg provides the same triple-receptor agonist compound in a mid-to-high concentration format suited to research protocols operating near the upper end of the clinical dose range. The pharmacology is identical across vial sizes: a 39-amino acid peptide with a C20 fatty diacid modification enabling albumin-mediated half-life extension and once-weekly subcutaneous delivery in clinical contexts.
The 15mg presentation is particularly practical for protocols modeling the higher dosing arms of the Phase 3 TRIUMPH program, or for multi-subject and longitudinal designs that consume larger quantities per study window. The compound's balanced GLP-1R, GIPR, and GCGR agonism makes it mechanistically distinct from both semaglutide and tirzepatide — a distinction that is experimentally meaningful when investigating the specific contribution of glucagon receptor activation to energy expenditure, hepatic lipid clearance, or anti-inflammatory effects in metabolic tissue.
Phase 3 TRIUMPH-4 results showing 28.7% mean weight loss at 68 weeks represent the most compelling clinical weight reduction data for any compound in this class. The 15mg vial ensures that research programs tracking these outcomes have adequate supply for the full arc of their protocols.
Mechanism of Action
Triple agonist at GLP-1R (appetite suppression), GIPR (insulin sensitization), and GCGR (hepatic lipolysis and energy expenditure); C20 fatty diacid modification enables once-weekly dosing via albumin binding.
Research Applications
Areas of peer-reviewed scientific inquiry where this compound has appeared.
- Obesity and adipose tissue research
- Type 2 diabetes and insulin resistance
- Knee osteoarthritis
- Obstructive sleep apnea
- Non-alcoholic steatohepatitis (NASH)
Key Findings from the Literature
- 01Phase 2: 24.2% mean weight loss at 48 weeks at highest dose
- 02Phase 3 TRIUMPH-4: 28.7% mean weight loss at 68 weeks
- 03Highest weight loss efficacy of any obesity pharmacotherapy in clinical trials to date
- 04Glucagon receptor agonism adds hepatic lipolysis absent from GLP-1-only agents
Certificates of Analysis1
Independent third-party lab reports for this peptide. Each CoA can be verified against its accession number at the testing lab.
1 independent test by Freedom Diagnostics Testing
| Test | Result |
|---|---|
| Purity (HPLC) | 99.71% |
| Identity (MS) | Pass |
| Endotoxins (LAL) | Pass |
Lab: Freedom Diagnostics Testing
Accession: 2606150160
Reports are verifiable against the issuing lab using the accession or batch identifier above.
Related Peptides
Other compounds in the metabolic research category.
metabolicRetatrutide
8mg
Eli Lilly's investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — demonstrating up to 28.7% weight loss in Phase 3 trials, the highest of any obesity pharmacotherapy to date.
metabolicRetatrutide
10mg
The 10mg vial format of retatrutide, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist, offering greater dosing flexibility for metabolic research protocols targeting weight loss, insulin resistance, and hepatic fat.
metabolicRetatrutide
20mg
The bulk research format of retatrutide — Eli Lilly's groundbreaking triple receptor agonist — providing the largest available quantity for high-throughput metabolic studies or extended longitudinal protocols.